Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Value of an Automated Ultrasound System in the Detection of Synovitis.

Ultrasound international open·2018
Same author

Erratum to: The influence of long distance running on sonographic joint and tendon pathology: results from a prospective study with marathon runners.

BMC musculoskeletal disorders·2016
Same author

The influence of long distance running on sonographic joint and tendon pathology: results from a prospective study with marathon runners.

BMC musculoskeletal disorders·2016
Same author

Disease burden, disease manifestations and current treatment regimen of the SAPHO syndrome in Germany: results from a nationwide patient survey.

Seminars in arthritis and rheumatism·2014
Same author

Ultrasound of synovitis in rheumatoid arthritis: advantages of the dorsal over the palmar approach to finger joints.

The Journal of rheumatology·2014
Same author

Relevance of grade 1 gray-scale ultrasound findings in wrists and small joints to the assessment of subclinical synovitis in rheumatoid arthritis.

Arthritis and rheumatism·2013
Same journal

Dendritic cell subsets in alopecia areata: focus on plasmacytoid dendritic cells and Langerhans cells in immune imbalance and therapeutic implications.

Expert review of clinical immunology·2026
Same journal

The role of immunosenescence and chronic medical conditions on the immune response to respiratory syncytial virus in older individuals.

Expert review of clinical immunology·2026
Same journal

Flow cytometry-based basophil and mast cell activation tests for IgE-mediated food and drug allergy: have we crossed the Rubicon?

Expert review of clinical immunology·2026
Same journal

An update on the pharmacotherapy of ANCA-associated vasculitis.

Expert review of clinical immunology·2026
Same journal

Targeting the cytokine storm: new therapies in the treatment of pediatric hemophagocytic lymphohistiocytosis.

Expert review of clinical immunology·2026
Same journal

Why is the antigen uptake receptor DEC205 (CD205) of interest?

Expert review of clinical immunology·2026
See all related articles

Related Experiment Video

Updated: Jan 10, 2026

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice
08:43

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Published on: January 31, 2020

7.3K

Etanercept: an introduction.

Mathias Grunke1, Joachim Robert Kalden

  • 1Department of Internal Medicine and Institute of Clinical Immunology and Rheumatology, University of Erlangen-Nuernberg, Medizinische Klinik III, Krankenhausstr. 12, 91054 Erlangen, Germany. Mathias.Gruenke@med3.imed.uni-erlangen.de

Expert Review of Clinical Immunology
|May 19, 2010
PubMed
Summary
This summary is machine-generated.

Etanercept, a biologic therapy, effectively treats autoimmune disorders like rheumatoid arthritis by inhibiting tumor necrosis factor. This review details its efficacy, long-term outcomes, and safety across various conditions.

More Related Videos

A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments
07:30

A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments

Published on: November 9, 2017

10.0K
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.4K

Related Experiment Videos

Last Updated: Jan 10, 2026

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice
08:43

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Published on: January 31, 2020

7.3K
A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments
07:30

A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments

Published on: November 9, 2017

10.0K
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.4K

Area of Science:

  • Immunology and Rheumatology
  • Biologic Therapies
  • Cytokine Inhibition

Background:

  • Autoimmune disorders involve chronic inflammation driven by key cytokines.
  • Tumor necrosis factor (TNF) is a critical cytokine in inflammatory processes.
  • Biologic therapies, including TNF inhibitors, offer new treatment avenues.

Purpose of the Study:

  • To introduce Etanercept, a TNF recombinant fusion protein.
  • To review the clinical efficacy of Etanercept in major autoimmune indications.
  • To present the latest data on long-term efficacy, radiologic outcomes, and safety.

Main Methods:

  • Review of existing literature and clinical trial data on Etanercept.
  • Analysis of efficacy in rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, and juvenile rheumatoid arthritis.
  • Evaluation of long-term outcomes, radiologic parameters, and safety profiles.

Main Results:

  • Etanercept demonstrates clinical efficacy across multiple autoimmune indications.
  • Newest data highlight positive long-term efficacy and favorable radiologic outcomes.
  • Safety data are reviewed, providing insights into the drug's tolerability.

Conclusions:

  • Etanercept is an effective biologic agent for managing autoimmune diseases.
  • The review provides a comprehensive overview of its current status and future potential.
  • Further research may explore its role in other indications and long-term management strategies.